Early Drug Development Group
Our preclinical and clinical operation structures rely on an interdisciplinary group of medical oncologists, pharmacologists and molecular biology experts with extensive experience in preclinical studies and clinical trials. We are capable of offering professional services covering all stages of your R&D program, to establish an attractive route to the clinic in a fast, efficient and cost effective manner.
Optimize, Innovate, Collaborate
We support medtech and biotech start-ups, pharmaceutical companies, investment fund groups and academic organizations in oncology to foster their R&D programs in a time- and cost-effective manner.
Management and execution of an efficient R&D program in oncology.
Broad capabilities in preclinical, pharmacokinetics and radiopharmacology studies to guide clinical development.
Assistance on preclinical, pharmacological and CMC approaches, regulatory strategies and Phase I clinical trials in oncology.
Advice on the reliability and feasibility of reported preclinical and clinical data.
Our strength relies on an interdisciplinary team of medical oncologists, pharmacologists and molecular biology experts with unparalleled experience in non-clinical and clinical trial studies.
We are interdisciplinary research group of medical oncologists, pharmacologists and molecular biology experts. We have performed several drug development programs with more than 20 companies -ranging from small biotech to the largest pharma companies- for the evaluation of over 20 different leads (at least 8 first-in-man) in oncology, covering both small molecules and monoclonal antibodies. Over the last years, we have established a long-standing network of trusted partner companies and world-class investigators experienced in early drug development and cancer research in oncology and immunology. This enable us to offer an attractive route to the clinic optimized in terms of time and costs.
Posted on 11th November 2019. E2DG form strategic collaboration with Fusion Antibodies to provide end-to-end service for oncology drug discovery companies. This deal between Fusion Antibodies & E2DG will allow to oncology drug discovery companies to benefit from Fusion Antibodies’ expertise in the discovery and early development of novel and highly developable therapeutic antibodies and from the experience of E2DG in preclinical efficacy and phase I/II oncology clinical trials. To get more information follow this link.
December 10-11, 2019. BioFit 2019, Marseille, France. Don't miss the opportunity to meet our team to discuss your project in oncology during BioFIt Conference!. To get more information on this conference follow this link.
November 11-13, 2019. BioEurope 2019, Hamburg, Germany. Please contact us to organize a meeting with E2DG team during BioEurope 2019. To get more information on this conference follow this link.
October 15-17, 2019. 1st COST Action CA17140 Conference. Riga, Latvia. Don't miss the opportunity to meet our CSO, Dr. Riveiro Maria Eugenia will be participating in the COST Management Committee meeting and the Conference. To get more information on this conference follow this link.
WANT TO LEARN MORE?
We look forward to learning about your specific needs, please contact us.